logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience produces first DehydraTECH-enabled CBD emulsion for licensed client

The super-concentrated DehydraTECH-enabled liquid nanoemulsion was shipped to the client's production facility for incorporation into its cold-brewed coffee production

Person holding beaker of CBD oil under a sunset
DehydraTECH is able to mask unwanted tastes, improve onset speed and increase the bioavailability of active pharmaceutical ingredients

Lexaria Bioscience Corp (OTCMKTS:LXRP) (CSE:LXX) announced that it has successfully processed its first CBD nanoemulsion for one of its licensed clients using its DehydraTECH technology. 

The British Columbia company provides emulsion services using DehydraTECH to qualifying clients who want to formulate ready-to-drink beverages containing CBD. 

Super-concentrated DehydraTECH-enabled liquid nanoemulsion was shipped to the client's production facility for incorporation into its cold-brewed coffee production and bottling line. Lexaria said it was able to process nearly 100,000 20 mg servings of DehydraTECH-empowered CBD concentrate.

READ: Lexaria Bioscience explains benefit of its CBD infused powders against backdrop of consumer concerns on potency

The client expects to begin distribution of its CBD beverage line in US stores soon, the company said.

DehydraTECH is able to mask unwanted tastes, improve onset speed and increase the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform. Essentially, the process allows CBD and other oils to be dehydrated into an odourless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

Additionally, Lexaria said it has amended the terms of its license for DehydraTECH enabled CBD-infused food ingredients originally announced in July. The company removed the exclusivity provisions and reduced the aggregate minimum fees payable over the term of the license to US$132,500.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 0.39 CAD

CSE:LXX
Market: CSE
Market Cap: $34.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bio Science files patent for technology to treat...

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs. Bunka telling Proactive this technology would potentially be used to improve...

on 21/4/20

2 min read